Join
Live feed
·
PRReleasevia Quantisnow
Vaccinex Inc. logo

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer's Disease

ByQuantisnow·Wall Street's wire, on your screen.
VCNX· Vaccinex Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VCNX (Vaccinex Inc.) and more on Quantisnow.